PRCT Relative Valuation
PRCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRCT is overvalued; if below, it's undervalued.
Historical Valuation
Procept Biorobotics Corp (PRCT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -27.69. The fair price of Procept Biorobotics Corp (PRCT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：35.43
Fair
-29.64
PE
1Y
3Y
5Y
Trailing
Forward
-103.04
EV/EBITDA
Procept Biorobotics Corp. (PRCT) has a current EV/EBITDA of -103.04. The 5-year average EV/EBITDA is -51.49. The thresholds are as follows: Strongly Undervalued below -134.70, Undervalued between -134.70 and -93.09, Fairly Valued between -9.88 and -93.09, Overvalued between -9.88 and 31.72, and Strongly Overvalued above 31.72. The current Forward EV/EBITDA of -103.04 falls within the Undervalued range.
-20.58
EV/EBIT
Procept Biorobotics Corp. (PRCT) has a current EV/EBIT of -20.58. The 5-year average EV/EBIT is -24.27. The thresholds are as follows: Strongly Undervalued below -49.13, Undervalued between -49.13 and -36.70, Fairly Valued between -11.85 and -36.70, Overvalued between -11.85 and 0.58, and Strongly Overvalued above 0.58. The current Forward EV/EBIT of -20.58 falls within the Historic Trend Line -Fairly Valued range.
4.70
PS
Procept Biorobotics Corp. (PRCT) has a current PS of 4.70. The 5-year average PS is 14.42. The thresholds are as follows: Strongly Undervalued below -1.10, Undervalued between -1.10 and 6.66, Fairly Valued between 22.18 and 6.66, Overvalued between 22.18 and 29.93, and Strongly Overvalued above 29.93. The current Forward PS of 4.70 falls within the Undervalued range.
-46.78
P/OCF
Procept Biorobotics Corp. (PRCT) has a current P/OCF of -46.78. The 5-year average P/OCF is -19.36. The thresholds are as follows: Strongly Undervalued below -50.57, Undervalued between -50.57 and -34.96, Fairly Valued between -3.75 and -34.96, Overvalued between -3.75 and 11.85, and Strongly Overvalued above 11.85. The current Forward P/OCF of -46.78 falls within the Undervalued range.
-58.63
P/FCF
Procept Biorobotics Corp. (PRCT) has a current P/FCF of -58.63. The 5-year average P/FCF is -37.08. The thresholds are as follows: Strongly Undervalued below -82.55, Undervalued between -82.55 and -59.82, Fairly Valued between -14.34 and -59.82, Overvalued between -14.34 and 8.39, and Strongly Overvalued above 8.39. The current Forward P/FCF of -58.63 falls within the Historic Trend Line -Fairly Valued range.
Procept Biorobotics Corp (PRCT) has a current Price-to-Book (P/B) ratio of 5.21. Compared to its 3-year average P/B ratio of 9.86 , the current P/B ratio is approximately -47.22% higher. Relative to its 5-year average P/B ratio of 8.74, the current P/B ratio is about -40.46% higher. Procept Biorobotics Corp (PRCT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.66%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.50% , the current FCF yield is about -100.00% lower.
5.21
P/B
Median3y
9.86
Median5y
8.74
-4.30
FCF Yield
Median3y
-4.66
Median5y
-4.50
Competitors Valuation Multiple
The average P/S ratio for PRCT's competitors is , providing a benchmark for relative valuation. Procept Biorobotics Corp Corp (PRCT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 42.76%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PRCT decreased by 56.00% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 58.37M to 83.33M.
The secondary factor is the Margin Expansion, contributed -28.47%to the performance.
Overall, the performance of PRCT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Procept Biorobotics Corp (PRCT) currently overvalued or undervalued?
What is Procept Biorobotics Corp (PRCT) fair value?
How does PRCT's valuation metrics compare to the industry average?
What is the current P/B ratio for Procept Biorobotics Corp (PRCT) as of Dec 05 2025?
What is the current FCF Yield for Procept Biorobotics Corp (PRCT) as of Dec 05 2025?
What is the current Forward P/E ratio for Procept Biorobotics Corp (PRCT) as of Dec 05 2025?